JP2004516038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004516038A5 JP2004516038A5 JP2002553118A JP2002553118A JP2004516038A5 JP 2004516038 A5 JP2004516038 A5 JP 2004516038A5 JP 2002553118 A JP2002553118 A JP 2002553118A JP 2002553118 A JP2002553118 A JP 2002553118A JP 2004516038 A5 JP2004516038 A5 JP 2004516038A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- protein
- arl4
- dad1
- chronic inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 230000001684 chronic effect Effects 0.000 claims 13
- 230000002757 inflammatory effect Effects 0.000 claims 13
- 208000023504 respiratory system disease Diseases 0.000 claims 13
- 102100039645 ADP-ribosylation factor-like protein 4A Human genes 0.000 claims 11
- 102100039104 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Human genes 0.000 claims 11
- 101000886015 Homo sapiens ADP-ribosylation factor-like protein 4A Proteins 0.000 claims 11
- 101000884921 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Proteins 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 11
- 210000002540 macrophage Anatomy 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 206010006458 Bronchitis chronic Diseases 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 6
- 206010006451 bronchitis Diseases 0.000 claims 6
- 208000007451 chronic bronchitis Diseases 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000004671 cell-free system Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25787800P | 2000-12-22 | 2000-12-22 | |
| PCT/EP2001/014838 WO2002052270A2 (en) | 2000-12-22 | 2001-12-15 | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004516038A JP2004516038A (ja) | 2004-06-03 |
| JP2004516038A5 true JP2004516038A5 (enExample) | 2005-04-21 |
Family
ID=22978162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002553118A Pending JP2004516038A (ja) | 2000-12-22 | 2001-12-15 | 慢性炎症性気道疾患の炎症性状態に陽性の影響を与える物質を同定するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20020150958A1 (enExample) |
| EP (1) | EP1346228A2 (enExample) |
| JP (1) | JP2004516038A (enExample) |
| CA (1) | CA2430610A1 (enExample) |
| MX (1) | MXPA03005325A (enExample) |
| WO (1) | WO2002052270A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070021360A1 (en) * | 2001-04-24 | 2007-01-25 | Nyce Jonathan W | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase |
| WO2003014745A2 (en) * | 2001-08-06 | 2003-02-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for identifying anti-inflammatory drugs |
| WO2004070058A1 (en) * | 2003-02-03 | 2004-08-19 | Bayer Healthcare Ag | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd |
| WO2005017113A2 (en) * | 2003-08-11 | 2005-02-24 | Lovelace Respiratory Research Institute, Et Al. | Metalloproteinase gene polymorphism in copd |
| WO2007044622A1 (en) | 2005-10-07 | 2007-04-19 | Yale University | Use of mif and mif pathway agonists |
| FR2904001A1 (fr) * | 2006-07-19 | 2008-01-25 | Galderma Res & Dev S N C Snc | Modulateurs de la udp-glucose ceramide glucosyltransferase dans le traitement de l'acne ou de l'hyperkeratinisation |
| US20150309012A1 (en) * | 2012-12-07 | 2015-10-29 | Baxter International Inc. | Anti-mif antibody cell migration assay |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| AU1235601A (en) * | 1999-10-29 | 2001-05-14 | Cytokine Pharmasciences, Inc. | Compounds having mif antagonist activity |
-
2001
- 2001-12-15 EP EP01988031A patent/EP1346228A2/en not_active Withdrawn
- 2001-12-15 CA CA002430610A patent/CA2430610A1/en not_active Abandoned
- 2001-12-15 WO PCT/EP2001/014838 patent/WO2002052270A2/en not_active Ceased
- 2001-12-15 MX MXPA03005325A patent/MXPA03005325A/es unknown
- 2001-12-15 JP JP2002553118A patent/JP2004516038A/ja active Pending
- 2001-12-21 US US10/029,654 patent/US20020150958A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bowdish | The aging lung: is lung health good health for older adults? | |
| Friedman | Hepatic fibrosis | |
| Chapman et al. | Mechanisms of airway hyper‐responsiveness in asthma: the past, present and yet to come | |
| PT1165110E (pt) | Antagonistas de hmg1 para tratamento de condicoes inflamatorias | |
| Mazzotta et al. | Different cytokine levels in thrombolysis patients as predictors for clinical outcome | |
| BRPI0518307A2 (pt) | mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3 | |
| Fujita et al. | Serum C-reactive protein levels in postmortem blood—an analysis with special reference to the cause of death and survival time | |
| BRPI0408802B8 (pt) | método para a detecção de uma lesão de célula tubular renal isquêmica e método para identificar a extensão desta lesão | |
| Zhang et al. | Tissue and BAL based biomarkers in asthma | |
| RU2008145510A (ru) | Композиции и способы диагностики и лечения астмы или других аллергических или воспалительных заболеваний | |
| NZ601815A (en) | Compositions and methods for treating and diagnosing asthma | |
| Molnár et al. | Assessment of heat provocation tests on the human gingiva: the effect of periodontal disease and smoking | |
| Johnson et al. | Airway smooth muscle and fibroblasts in the pathogenesis of asthma | |
| Fust et al. | Alterations in lung mechanics in decorin-deficient mice | |
| Kang et al. | Neuroprotective effects of magnesium-sulfate on ischemic injury mediated by modulating the release of glutamate and reduced of hyperreperfusion | |
| Stelmach et al. | Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis | |
| JP2004516038A5 (enExample) | ||
| Song et al. | CTRP3 alleviates myocardial ischemia/reperfusion injury in mice through activating LAMP1/JIP2/JNK pathway | |
| Boesen et al. | Interleukin-1β, but not interleukin-6, enhances renal and systemic endothelin production in vivo | |
| RU2008116567A (ru) | Биомаркеры | |
| Mitsunobu et al. | Enhanced production of leukotrienes by peripheral leukocytes and specific IgE antibodies in patients with chronic obstructive pulmonary disease | |
| JP2012520446A5 (enExample) | ||
| Wang et al. | Serum neutrophil gelatinase-associated lipocalin and proinflammatory cytokines in pigs with septic versus non-septic acute kidney injury | |
| Mortensen et al. | Ambulatory arterial stiffness index in Turner syndrome: the impact of sex hormone replacement therapy | |
| Burgmann et al. | Using urea as an endogenous marker of bronchoalveolar lavage dilution |